Office Number: 203-815-5782
CaroGen Expands its Board of Directors and Development Leadership Team
Farmington, CT - April 17, 2017: CaroGen today announced an important addition to its Board of Directors (Dr. Jo Viney) and two key senior executive level scientists (Dr. Steven Mason and Dr. Timur Yarovinsky) to its immunotherapy discovery and development team. Click here to read the full press release
CaroGen and University of Connecticut Colon Cancer Immunotherapy Collaboration Highlighted in Colon Cancer News Today
Farmington, CT - January 26, 2017: CaroGen and researchers at the University of Connecticut have initiated a collaboration on development of a colon cancer immunotherapy. This collaboration was highlighted in Colon Cancer News Today. Click here to read the full article.
UCONN Health Researchers Collaborate with CaroGen Corporation to Develop Vaccine to Treat Colon Cancer
Farmington, CT - November 8, 2016: The University of Connecticut and CaroGen Corporation, an emerging immunotherapy company, today announced a collaboration aimed at developing a therapeutic vaccine for treatment of patients with colon cancer. CaroGen’s proprietary technology platform will be applied to a specific target studied by UConn Health’s Dr. Kepeng Wang Ph.D., Assistant Professor of Immunology. Click here to read the full press release
CaroGen Forms Zika Vaccine Consortium
Farmington, CT - November 7, 2016: CaroGen Corporation, announced today that it has formed a consortium comprising CaroGen, the University of Connecticut and Yale University School of Medicine scientists to accelerate the development of a Zika virus vaccine. Click here to read the full press release.
CaroGen Raiess $1M in Series A Funds
Farmington, CT - October 19, 2016: CaroGen Corporation announced today that it has raised $1 million dollars through GP Fortune Investment Partners (GPFI), LLC, to advance the company's Heptatis B Virus (HBV) immunotherapy. Click here to read the full press release.
CaroGen in the News:
August 8, 2016: CaroGen’s CEO Bijan Almassian was profiled by the Hartford Business Journal where he discusses CaroGen's technology, products to treat or prevent Hepatitis B, Zika and C. difficile infections and financing. Click here to read the full interview.
July 5, 2016: Connecticut Senators Murphy and Blumenthal pushing for Zika virus response funding. Click here for the story.
SPARK Commercialization Grant Award for C. difficile Vaccine
Farmington, CT - April 18, 2016: CaroGen announced today that University of Connecticut collaborator, Dr. Kamal Khanna, was awarded a SPARK Commercialization Fund grant from the University of Connecticut. The grant is to support the research and development of a VLV-based vaccine against C. difficile infection. The award will support the creation of candidate VLV vaccines and testing their immunogenicity in preclinical models. Click here to read the award notification from SPARK.
CT Backs CaroGen’s Quest to Fight Cancer, Hepatitis B
March 7, 2016: An interview with CaroGen’s President and CEO was published in the Hartford Business Journal where he provides an update on CaroGen’s product development: Click here to read the full interview.
CaroGen Announces Publication of HBV Vaccine Preclinical Research
Hamden CT - August 17, 2015 - CaroGen Corporation, an emerging vaccine company, today announced the electronic publication of a research article entitled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection,” which appeared in the August online issue of the Journal of Virology.
CaroGen Fostering Vaccine Development Collaborations with Yale & UConn and Establishing Laboratory
Farmington CT – January 5, 2015 – CaroGen Corporation today announced that it has chosen UConn’s Technology Incubation Program (TIP) in Farmington to establish a laboratory footprint. This expansion will allow CaroGen to more aggressively pursue the advancement of its proprietary virus-like vesicle (VLV) vaccine technology, development of its HBV vaccine program and evaluation of other potential candidate infectious disease vaccines.
CaroGen Receives $500,000 Investment from Connecticut Bioscience Innovation Fund (CBIF)
Hamden CT – December 10, 2014 – CaroGen has been awarded $500,000 from the CBIF to support the continued development of CaroGen's therapeutic Hepatitis B Virus (HBV) vaccine.
CaroGen Wins Entrepreneur Innovation Award from CTNext
Hamden CT – April 3, 2014 – CaroGen was awarded a $10,000 grant by CTNext, a component of Connecticut’s innovation ecosystem to support the success of companies and entrepreneurs, to further support development of its therapeutic vaccine for chronic Hepatitis B (CHB) viral infection.
Hepatitis B Virus Global Statistics
• 2 Billion people have been infected (1 out of 3 people).
• 240 Million people are chronically infected.
• 10-30 Million will become infected each year.
• Chronic HBV infection is the major cause of hepatocellular carcinoma
• Over 500,000 people die each year from HBV and its complications
Global Market for HBV Drugs
• HBV anti-viral drugs: $3.1 Billion will hit $4.4 Billion (2019)
• Drugs do not cure chronic disease
• No FDA approved and marketed therapeutic vaccine
Global Market for Vaccines
• Human and animal vaccines: $25 Billion and projected to grow to $100 Billion (2024)
• Hepatitis B virus vaccines: $1.0 Billion and projected to grow to 1.8 Billion (2018)
The Company has secured more than $3 million to fund its vaccine development and operations. Most of the financing has come from Connecticut Innovations (http://www.ctinnovations.com), followed by G. P. Healthcare (www.gerpanghealthcare.com), Shandong Province, China; and from non-dilutive funding sources such as grants and awards. We plan to raise an additional $10 million in a Series B Round of financing within the next 12 months. The proceeds of these funds will be used to select an HBV clinical vaccine candidate; to perform preclinical GLP toxicology and GMP manufacturing studies needed for filing an Investigational New Drug (IND) application; and to complete Phase I human clinical trial.